Back Kreymann, B, Ghatei, MA, Williams, G, Bloom, SR (5 Dec 1987), The Lancet , 330/8571, 1300-04
These side effects apply to the GLP-1 medication class based on studies of FDA-approved products
Authors Footnotes Editorial, page 271 Study Funding A.J
Countries with known restrictions or additional requirements include: Japan : Requires advance notification (yakkan shoumei) for quantities exceeding a 1-month supply or for bringing needles/injection devices
We elucidated previously unnoted ways in which GLP-1RAs curbed RA pathology via direct suppression of the cGAS-STING signaling pathway to inhibit chondrocyte ferroptosis and concomitantly induced macrophage M2 polarization
If youre building in this space, the path forward isnt always straightforward, but it is navigable with clarity, the right insights, and a team that understands the operational, clinical, and product layers behind a GLP-1 service